PCSK9 and the Liver-Brain Axis: A Novel Therapeutic Target for Alcohol Use Disorder

被引：0
|
作者：
Lee, Jisoo [1 ]
Mukhopadhyay, Partha [1 ]
Matyas, Csaba [1 ]
Trojnar, Eszter [1 ]
Paloczi, Janos [1 ]
Rosoff, Dan [1 ]
Yang, Yuan Ru [1 ]
Blank, Brandon [1 ]
Savage, Cody [1 ]
Vendruscolo, Janaina [1 ]
Koob, George [1 ]
Vendruscolo, Leandro [1 ]
Pacher, Pal [1 ]
Lohoff, Falk [1 ]
机构：
[1] NIAAA, NIH, Bethesda, MD USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2019年 / 44卷 / SUPPL 1期
关键词：
Alcohol Use Disorder; Proprotein Convertase Subtilisin/Kexin 9; Liver-Brain Axis; Alcohol-Induced Inflammation; Cerebrospinal Fluid;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
W270
引用
收藏
页码：530 / 530
页数：1
相关论文
共 50 条
  • [1] PCSK9 and the Gut-Liver-Brain Axis: A Novel Therapeutic Target for Immune Regulation in Alcohol Use Disorder
    Lee, Ji Soo
    O'Connell, Emma M.
    Pacher, Pal
    Lohoff, Falk W.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (08)
  • [2] PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
    Lee, Ji Soo
    Mukhopadhyay, Partha
    Matyas, Csaba
    Trojnar, Eszter
    Paloczi, Janos
    Yang, Yuan Ru
    Blank, Brandon A.
    Savage, Cody
    Sorokin, Alexander V.
    Mehta, Nehal N.
    Vendruscolo, Janaina C. M.
    Koob, George F.
    Vendruscolo, Leandro F.
    Pacher, Pal
    Lohoff, Falk W.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [3] PCSK9 INHIBITION AS A NOVEL THERAPEUTIC TARGET FOR ALCOHOLIC LIVER DISEASE
    Lee, J.
    Mukhopadhyay, P.
    Matyas, C.
    Trojnar, E.
    Paloczi, J.
    Yang, Y. R.
    Blank, B. A.
    Savage, C.
    Sorokin, A. V.
    Mehta, N. N.
    Vendruscolo, J. C. M.
    Koob, G. F.
    Vendruscolo, L. F.
    Pacher, P.
    Lohoff, F. W.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2020, 44 : 45 - 45
  • [4] PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
    Ji Soo Lee
    Partha Mukhopadhyay
    Csaba Matyas
    Eszter Trojnar
    Janos Paloczi
    Yuan Ru Yang
    Brandon A. Blank
    Cody Savage
    Alexander V. Sorokin
    Nehal N. Mehta
    Janaina C. M. Vendruscolo
    George F. Koob
    Leandro F. Vendruscolo
    Pal Pacher
    Falk W. Lohoff
    Scientific Reports, 9
  • [5] PCSK9 as a Therapeutic Target in Atherosclerosis
    Ali J. Marian
    Current Atherosclerosis Reports, 2010, 12 (3) : 151 - 154
  • [6] PCSK9 as a therapeutic target of dyslipidemia
    Seidah, Nabil G.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (01) : 19 - 28
  • [7] Alcohol, insulin resistance and the liver-brain axis
    de la Monte, Suzanne
    Derdak, Zoltan
    Wands, Jack R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 33 - 41
  • [8] PCSK9 as a therapeutic target for cardiovascular disease
    Zhang, Pei-Ying
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (03) : 810 - 814
  • [9] PCSK9:: a promising therapeutic target for dyslipidemias?
    Lambert, G
    Krempf, M
    Costet, P
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2006, 17 (03): : 79 - 81
  • [10] PCSK9: A Potential Therapeutic Target for Sepsis
    Yuan, Yuan
    Wu, Wei
    Sun, Shanshan
    Zhang, Yi
    Chen, Zhi
    JOURNAL OF IMMUNOLOGY RESEARCH, 2020, 2020
12345